Obsidian Therapeutics
Cambridge, United States· Est.
Obsidian Therapeutics engineers controllable cell and gene therapies, primarily in oncology, using its cytoDRiVE® platform to regulate protein expression.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $160M
About
Obsidian Therapeutics engineers controllable cell and gene therapies, primarily in oncology, using its cytoDRiVE® platform to regulate protein expression.
Cell TherapyGene TherapyOncology
Funding History
1Total raised:$160M
Series C$160M